SCHEMBL2493345

SCHEMBL2493345

COc1ccc(S(=O)(=O)N2CCc3ccccc3C2CC(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 3/20 0.55
THRB P10828 1/20 0.55
MMP1 P03956 5/20 0.52
MMP2 P08253 3/20 0.52
MMP9 P14780 3/20 0.52
MMP12 P39900 3/20 0.52
MMP14 P50281 3/20 0.52
MMP15 P51511 3/20 0.52
MMP16 P51512 3/20 0.52
MMP26 Q9NRE1 3/20 0.52
MMP7 P09237 2/20 0.52
LMNA P02545 4/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 3/20 0.52
RECQL P46063 2/20 0.52
MEN1 O00255 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644906 0.90 THRB (0.58) TAS2R14THRBMMP1MMP2MMP9
SCHEMBL5915267 0.85 THRB (0.55) THRBLMNAMAPTALDH1A1RECQL
SCHEMBL6953145 0.83 THRB (0.51) THRBLMNAMAPTALDH1A1RECQL
SCHEMBL2487757 0.80 BDKRB1 (0.59) THRBMMP9LMNAMAPTALDH1A1
SCHEMBL3302250 0.80 MMP1 (0.57) TAS2R14MMP1MMP2MMP9MMP12
SCHEMBL14427251 0.80 MMP1 (0.57) TAS2R14MMP1MMP2MMP9MMP12
SCHEMBL8802699 0.80 MMP1 (0.58) TAS2R14MMP1MMP2MMP9MMP12
SCHEMBL4692409 0.80 TAS2R14 (0.54) TAS2R14MMP1MMP2MMP9MMP12
SCHEMBL20788125 0.80 OPRM1 (0.59) MMP1MMP2MMP9MMP12MMP14
SCHEMBL14427161 0.78 MMP1 (0.76) MMP1MMP2MMP9MMP12MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US disclosed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US disclosed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253669-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 TAS2R14 701/4885THRB 4066/4885MMP1 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.